Please assess the completion status of the following clinical trial:

Trial Title: Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients hospitalized for chemotherapy or blood/bone marrow transplant.~2. Age 20 - 75~3. Not currently regularly taking any prescribed sleeping pill more often than 4x/week.~4. Can tolerate oral medication.~Exclusion Criteria:~1. Patients with a current history of substance abuse~2. Patients with a history of allergic response to Lunesta.~3. Patient who require additional oral or parenteral opioids after starting PCA opioid treatment.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- eszopiclone (Type: ACTIVE_COMPARATOR): active drug
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).